(2002; 166 pages)
1. Patient/consumer protection should be the first priority of regulatory authorities in their approach to e-commerce. National authorities should endeavour to ensure that patients have the same level of protection whether they purchase pharmaceuticals through legitimate Internet sites or through the traditional channels.
2. Regulatory authorities should improve the information contents of their websites and establish appropriate programmes, including mass media campaigns, aimed at providing unbiased information and warn the public on the possible risks of unregulated pharmaceutical ecommerce.
These programmes must be designed in a way that ensures that they effectively reach health professionals and consumers.
3. National authorities should establish and encourage the use of simple mechanisms for consumers and health professionals to report illegal sites and negative experience they have had with e-commerce.
4. WHO should establish and maintain a list of national focal points and circulate it to all regulatory authorities in order to foster international collaboration in combating illegal pharmaceutical e-commerce.
5. WHO should continue to create opportunities, through international meetings of national regulatory officials, for discussing and foster awareness on the public-health issues related to pharmaceutical e-commerce.
6. Progress should be reported back to the ICDRA.